Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/f96s4d48

"NEXT-FRONTIER TECHNOLOGIES IN CERVICAL CANCER PREVENTION: A GLIMPSE INTO TOMORROW'S MEDICINE"

Dr Rabia Bibi[1*], Dr Zareena Begum[2], Dr. Amna Najam[3], Sania Murad[4], Dr Sajida Rasheed[5], Dr. Amber Shams[6]

[1*]Liaquat University of Medical and Health Sciences, Jamshoro
[2]Assistant Professor, Saidu medical college swat
[3]Assistant Professor Obs/Gynae, Al-Nafees Medical College and Hospital Islamabad.
[4]MBBS, CHPE, FCPS Gynae ObsMbbs Uni: Liaquat National Medical College Karachi
[5]Dow university of health sciences Karachi
[6]Liaquat University of Medical and Health Sciences, Jamshoro

***Corresponding Author:** Dr Rabia Bibi
* Liaquat University of Medical and Health Sciences, Jamshoro

Abstract
The incorporation of new revolutions in health, such as AI, telehealth, nanotechnology and genomics, among others, could revolutionize cervical cancer prevention through the application of individualized, risk-stratified approaches. These developments help to identify new biomarkers for early diagnosis, survival risk and efficacy of treatment. Digital health enables data management and analysis, therefore improving disease diagnosis, treatment and drug screening. Artificial intelligence tools sift through complicated data sets to look for patterns and even to forecast what might happen, assiting caregivers with making informed decisions that enhance patient care. Integration of these technology combinations provides unprecedented opportunities for early detection, individualized management, increased availability of care, and identification of those at highest risk for, eg, cervical cancer in resource-poor countries with the potential for reducing the global burden of cervical cancer.

Introduction
Cervical cancer, primarily caused by persistent human papillomavirus (HPV) infections, represents a major global health problem, especially in low- and middle-income countries where it is usually diagnosed at an advanced stage (Burmeister et al., 2024; Wu et al., 2017). Novel techniques and approaches are needed to enhance the prophylaxis, early diagnosis, and treatment response, ultimately leading to the WHO ambitious commitment of eliminating cervical cancer in the next couple of decades (McCormack et al., 2021). Studies are aimed to determine the determinants of (oncogenic) HPV infection, assessing prophylactic as well as therapeutic vaccines, and developing cervical cancer screening strategies that use HPV testing in combination with other technologies to back up cytology (Franco et al., 2001). Multiple approaches to the primary prevention of the disease including; risk avoidance, dietary modification, use of chemopreventive agents, and HPV vaccine, and the secondary prevention of the disease, via enhanced Pap smear techniques, and HPV typing for triage, are under investigation (Rock et al. The advent of new biotechnologies, developing screening approaches and innovative therapeutic strategies are especially encouraging for the future of cervical cancer prevention: they may have the potential to shift the battle against this disease from control to eradication (Ngan et al., 2011; Rock et al., 2000).

Innovations in Prevention and Screening Methodologies

The future of cervical cancer screening depends on combining modern techniques to screening programs resulting in improved sensitivity, specificity and availability especially in underprivileged areas.

Such interventions are indeed critical to strengthening the utilization and uptake of HPV vaccines, a mainstay of primary prevention (Bosch et al., 2012). Although HPV vaccination has been available for more than 10 years,its coverage has been uneven worldwide, and many LMIC face specific challenges to access and implementation (Gaffney et al., 2018; Sanjosé et al., 2019). Innovative vaccine delivery platforms including microneedle patches and thermostable formulations are emerging to address the limitation of traditional injectable vaccines, particularly in low-resource settings or in the context of infrastructure and logistics (Bhatla et al., 2021; Sharma et al., 2023). In addition, investigations are ongoing to design multivalent vaccines providing broader coverage to a greater number of HPV genotypes, including non-16/18 high-risk types—thus possibly increasing the long-term impact of vaccination strategies (Harden & Münger, 2016).

Besides, the application of AI and ML techniques within cervical screening have great potential to improve the sensitivity and specificity of screening efficiency in a time-efficient manner. The AI-based algorithms have been shown to interpret images of cervical cytology and histopathology with incredible accuracy, which may help in reducing the false negative and false positive rates. In addition, these algorithms can be implemented in resource-limited settings via mobile technologies for health (mHealth) to provide tele-health diagnosis and access to care for isolated women in a timely fashion. Further, discovery of new biomarkers and molecular diagnostics are also developed to identify the women at risk for the high grade cervical cancer in which targeted screen and invade strategies can be adapted.

The Role of Technology in Enhancing Screening Efficacy

Cervical cancer screening programs are evolving towards the implementation of novel technologies for improved effectiveness and increasing coverage.

Conventional screening techniques, including the Pap smears have issues in the sensitivity and specificity, and hence various alternative approaches with enhanced accuracy have been developed (Shandilya et al., 2024). HPV DNA test has proven to be an extremely sensitive method of screening, particularly for detection of high-risk HPV infections that have the capacity to give rise to cervical cancer. HPV DNA testing has been shown in several studies to be more successful than cytology in primary screening and has been integrated into screening guidelines in many countries. Moreover, improvements in molecular diagnostics have facilitated the creation of point-of-care HPV testing devices that may be utilized in low-income regions and provide rapid and accurate cancer screening outcomes. They can be used by less trained health-workers, rendering them suitable for rural or isolated areas with limited access to laboratory facilities.

Another promising technology in cervical cancer screening is colposcopy with enhanced visualization techniques. Colposcopy involves the examination of the cervix using a magnifying instrument to identify abnormal areas that may require biopsy.

Addressing Implementation Challenges and Future Directions

Cervical cancer screening programs are evolving towards the implementation of novel technologies for improved effectiveness and increasing coverage.

Conventional screening techniques, including the Pap smears have issues in the sensitivity and specificity, and hence various alternative approaches with enhanced accuracy have been developed (Shandilya et al., 2024). HPV DNA test has proven to be an extremely sensitive method of screening, particularly for detection of high-risk HPV infections that have the capacity to give rise to cervical cancer. HPV DNA testing has been shown in several studies to be more successful than cytology in primary screening and has been integrated into screening guidelines in many countries. Moreover, improvements in molecular diagnostics have facilitated the creation of point-of-care HPV testing devices that may be utilized in low-income regions and provide rapid and accurate cancer screening

outcomes. They can be used by less trained health-workers, rendering them suitable for rural or isolated areas with limited access to laboratory facilities.

Literature Review:
Literature related to cervical cancer prevention is broad, including aspects from screening technologies, strategies for vaccination, treatment approaches, and implementation barriers.
Various screening tests, such as cytology, HPV DNA testing and visual inspection with acetic acid, have been studied for their efficacy in cancer precursors detection and the number of cervical cancers prevented (Amir et al., 2023). HPV DNA testing is more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) (Bhat, 2022). The economic impact of population-based HPV vaccination programmes has also been investigated by evaluating the cost-effectiveness of different vaccination strategies in different populations (Gakidou et al., 2008). HPV immunization is a promising tool for control of cervical cancer, particularly in settings with restrictions on screening programs (Murillo et al., 2016). Cost-effectiveness of parallel Papanicolaou, and human papilloma virus DNA testing for cervical screening has been assessed in the Indian setting using a Markov model to compare the lifetime costs and effects (Chauhan et al., 2020). The model showed that for the most cost-effective use of resources, a strategy of HPV DNA testing every 5years for women aged 30–65years is indicated, although the quadrivalent HPV vaccine among 12-year-old girls is also cost-effective if the cost is low (Bobdey et al., 2016; Sankaranarayanan et al., 2008; Villa, 2012). Through dozens of studies, many authors have investigated the influence of socioeconomic factors, cultural beliefs, and indicators of healthcare access on the incidence of cervical cancer and mortality, with health inequity in terms of disease burden noted between various demographics (Momenimovahed et al., 2022; Villa 2012).

Methodology
To obtain a complete characterization of the landscape of next-frontier technologies for cervical cancer prevention, a multifaceted approach will be used that integrates literature reviews, data mining, consultation with experts, and a case study review. The first stage is a systematic review of extant scientific literature, including peer-reviewed manuscripts, conference proceedings, and technical reports, to distill the universe of emerging technologies and strategies in cervical cancer prevention. Databases including PubMed, Scopus, Web of Science and Cochrane Library will be searched based on appropriate key words and search terms (i.e. cervical cancer, prevention, screening, vaccination, HPV, artificial intelligence, nanotechnology and biomarkers). In addition, we will use data mining methods to identify information in publicly available datasets (eg, cancer registries; clinical trial databases; epidemiologic surveys) on the prevalence, incidence, and mortality of cervical cancer, and on the efficacy of various methods of prevention. Typical will include expert interview with researchers, clinical practitioners, and public policy advocates in the area of cervical cancer prevention to learn about the current state of the art, potential new directions, and their translation to Practical Experience of US Women with Vacuum Assisted Bi-Opsy (VABB) Second Look Ultrasound Guides by Andrea Mahnke APN CNP Speaker's Name: Andrea Mahnke APN CNP Institution: University of Toledo Medical Center Practice: A Private Practice in NW Ohio Contact #: 419-472-1168 E-mail: andrea.mahnke@gmail.com?> Utility Techniques; Practice Interested in New techniques to support patient care for Vacuum Assisted Biopsy of the small lesions identified on screening mammogram or sonogram. Finally, posters on case study analysis will focus on the feasibility, cost-effectiveness, and scalability of new technologies and strategies as applied in field settings.

Results
Next-frontier approaches to cervical cancer prevention The evaluation of next-frontier technologies for cervical cancer prevention highlights a rapidly evolving field with novel techniques and transformative potential.

AI is proving to be a valuable means of improving the sensitivity and efficiency of cervical cancer screening, and multiple studies have shown that machine learning (ML) based algorithms achieve satisfactory outcomes for automated diagnosis of Pap smear images or detection of precancerous lesions (Lu et al., 2020).

Emerging telehealth and mobile health (mHealth) technologies are increasing the access to cervical cancer screening and prevention services, not only in underserved and remote regions, but also through smartphone apps and remote monitoring devices. For example, the application of AI in medical diagnosis, particularly in cervical cancer screening and diagnosis is also commendable, overcoming the cumbersome and difficult-to-reach path of precise diagnosis despite the progress of science and technology (Hou et al., 2022). AI provides solutions to solve the human errors and interobserver variations related drawbacks of the based traditional screening(Gentile & Malara, 2024). Nanotechnology-mediated strategies are providing novel options for the targeted delivery of drugs and for imaging, promising to increase effectiveness and minimize toxicities of the treatments of cervical cancer and to promote early diagnosis of precancerous lesions. The incorporation of genomics and molecular biomarkers into cervical cancer screening and prevention is leading to the development of personalized and risk-stratified strategies is the identification of novel biomarkers for early detection, risk assessment, and treatment response prediction. The integration of these next-frontier technologies offers vast potential to transform cervical cancer prevention, and therefore alleviate the worldwide burden of this disease (Farina et al., 2022; Goel et al., 2025; Tiwari et al., 2025; Vargas-Santiago et al., 2025).

The analysis also indicates that the cancer space has made considerable progress in adopting digital health technologies over the last decade and has significant work to pursue to ensure that these tools are seamlessly integrated into the cancer control systems required to achieve equitable outcomes across populations (Hesse et al., 2021). The proliferation of digital devices and digital technologies for capturing and creating data, combined with a rapid increase in data storage capacity and computational power make it possible to store and analyze vast databases at an unprecedented scale (Papachristou et al., 2023). The pervading use of digital health solutions, including the use of electronic health records, has resulted in big data on patients in both structured and unstructured formats (Egger et al., 2018).

The advancement and applications of AI and ML have been revolutionizing healthcare with enhanced disease diagnosis, treatment planning and drug discovery (Patel et a1, 2020; Thacharodi et ai, 2024). AI, analytics and data visualisations AI algorithms could be used to examine complex health data, recognize patterns and predict the application of different interventions to help health workers to make decisions and provide better care to patients (Chang, 2019). Again, the application of AI in genomic medicine is another significant progress in human genetic predisposition to diseases endemic to Africa (Alaran et al., 2025). AI has been applied on NGS sequencing data and HR imaging, in the predict and diagnose early on-set of disease (Iqbal et al., 2021).

Discussion

The introduction of next-frontier technologies has the potential to revolutionize cervical cancer prevention strategies and outcomes worldwide (García-Saisó et al., 2024). Digital solutions seek to fill the current gap between traditional medical practice and the patient centered future of medicine (Jacobs et al., 2024). The introduction of artificial intelligence and telehealth for CC prevention programs combined with nanotechnology and genomics for personalized treatment raises unprecedented prospects of early detection and access to care, especially among the underserved communities (Aerts & Bogdan-Martin, 2021). Through the use of AI, providers can improve the accuracy and efficiency of cervical cancer screening, leading to earlier detection of precancerous lesions and lower rates of invasive procedures. Examination of telehealth and mHealth approaches for increasing the reach of cervical cancer prevention services in relatively isolated and rural areas will address such geographical barriers and enhance access to care among women who are typically beyond the reach of conventional health care settings.

In addition, nanotechnology-based strategies seem to offer potential for precise drug delivery and imaging, leading to improved and less toxic treatment of cervical cancer. The incorporation of genomics and biomarkers into cervical cancer screening and prevention provides opportunities for more personalized and risk-stratified strategies so that health care providers can better individualize prevention programs to the risk profile of a woman. AI applications are also growing in areas such as cardiology, gastroenterology and radiology, which will likely allow for better disease detection, therapeutic strategies and patient prognostication (Alum & Ugwu, 2025). AI has the potential to capitalize on the vast quantities of data to innovate drug repurposing (the use of known drugs for new applications) and accelerate the drug discovery process, with the potential to lower drug development costs and time (Oualikene-Gonin et al., 2024). By virtue of their ability to decentralize medical testing, obviate the requirement of cumbersome patient's visits for sample harvesting and centralized laboratory testing and accommodate personalized medicine regimens at remote markers (Haghayegh et al., 2024), point-of-care wearables boost in their prospects.

AI in Medicine and CS Innovations Artificial intelligence developments in medicine indicate the kinds of things that can be achieved within CS to solve complex problems in fields that have lots of data but poor theoretical underpinnings (Briganti & Moine, 2020). Personalized medicine AI enables personalized analysis of genetic, demographic, and lifestyle data to give customized treatment advice, which is especially useful in oncology when AI is able to predict patient response to different chemotherapy drugs, thus improving patient treatment course.Property of Magnetic Resonance Imaging in Personalized Medicine and Oncology 6.Future For individualized medicine and oncology, MRI has brought a quite different future (Li et al., 2024). AI uses aggregate medical data to detect patterns and correlations that might be imperceptible to human analysis (Varnosfaderani & Forouzanfar, 2024). It is this potential ability to diagnose both earlier and more accurately that makes AI capable of finding the subtle signs of disease in medical scans, in genetic information, in patient records. The use of AI in cancer imaging may result in automated image interpretation, leading to the possible evolution of radiographic detection, intervention management, and subsequent follow-up (Bi et al., 2019). AI based applications have shown potential to lead to better treatment strategies providing precision, personalization and efficiency by analyzing large complex data sets to delve into tumor genomics, proteomics and other molecular profiles to gain insights into the molecular mechanisms that drive cancer (Bongurala et al., 2025).

Conclusion

Finally, the synergy of next-frontier technologies including artificial intelligence, telehealth, nanotechnology, and genomics bodes very well for disruptive innovations in cervical cancer prevention. Using these high-end platforms, health professionals can better screen for this disease at an early stage, personalize treatments based on individual condition, strive for more healthcare services and eventually lower the burden of this disease worldwide (Banumathi et al., 2025). Yet, it is important to take on the barriers of technology adoption such as data privacy, regulations, and skill and infrastructure challenges.

References

1. Aerts, A., & Bogdan-Martin, D. (2021). Leveraging data and AI to deliver on the promise of digital health. International Journal of Medical Informatics, 150, 104456. https://doi.org/10.1016/j.ijmedinf.2021.104456
2. Alaran, M., Lawal, S. K., Jiya, M. H., Egya, S. A., Ahmed, M. M., Abdulsalam, A., Haruna, U. A., Musa, M. K., & Lucero-Prisno, D. E. (2025). Challenges and opportunities of artificial intelligence in African health space. Digital Health, 11. https://doi.org/10.1177/20552076241305915
3. Alum, E. U., & Ugwu, O. P.-C. (2025). Artificial intelligence in personalized medicine: transforming diagnosis and treatment. Deleted Journal, 7(3). https://doi.org/10.1007/s42452-025-06625-x

   Amir, S. M., Idris, I. B., Said, Z. M., Yusoff, H. M., & Manaf, M. R. A. (2023). A Comparison of the National Cervical Cancer Policies in Six Developing Countries with the World Health Organization Recommendations: A Narrative Review [Review of A Comparison of the National Cervical Cancer Policies in Six Developing Countries with the World Health Organization Recommendations: A Narrative Review]. Iranian Journal of Public Health. Knowledge E. https://doi.org/10.18502/ijph.v52i6.12952

4. Banumathi, K., Venkatesan, L., Benjamin, L. S., Vijayalakshmi, K., & Satchi, N. S. (2025). Reinforcement Learning in Personalized Medicine: A Comprehensive Review of Treatment Optimization Strategies [Review of Reinforcement Learning in Personalized Medicine: A Comprehensive Review of Treatment Optimization Strategies]. Cureus. Cureus, Inc. https://doi.org/10.7759/cureus.82756
5. Bhat, D. (2022). The 'Why and How' of Cervical Cancers and Genital HPV Infection [Review of The 'Why and How' of Cervical Cancers and Genital HPV Infection]. CytoJournal, 19, 22. Medknow. https://doi.org/10.25259/cmas_03_03_2021
6. Bhatla, N., Meena, J., Kumari, S., Banerjee, D., Singh, P., & Natarajan, J. (2021). Cervical Cancer Prevention Efforts in India [Review of Cervical Cancer Prevention Efforts in India]. Indian Journal of Gynecologic Oncology, 19(3). Springer Science+Business Media. https://doi.org/10.1007/s40944-021-00526-8
7. Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., Mak, R. H., Tamimi, R. M., Tempany, C. M., Swanton, C., Hoffmann, U., Schwartz, L. H., Gillies, R. J., Huang, R. Y., & Aerts, H. J. W. L. (2019). Artificial intelligence in cancer imaging: Clinical challenges and applications [Review of Artificial intelligence in cancer imaging: Clinical challenges and applications]. CA A Cancer Journal for Clinicians, 69(2), 127. Wiley. https://doi.org/10.3322/caac.21552
8. Bobdey, S., Sathwara, J., Jain, A., & Balasubramaniam, G. (2016). Burden of cervical cancer and role of screening in India. Indian Journal of Medical and Paediatric Oncology, 37(4), 278. https://doi.org/10.4103/0971-5851.195751
9. Bongurala, A. R., Save, D., & Virmani, A. (2025). Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1533910
10. Bonjour, M., Charvat, H., Franco, E. L., Piñeros, M., Clifford, G. M., Bray, F., & Baussano, I. (2021). Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. The Lancet Public Health, 6(7). https://doi.org/10.1016/s2468-2667(21)00046-3
11. Bosch, F. X., Tsu, V., Vorsters, A., Damme, P. V., & Kane, M. (2012). Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases [Review of Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases]. Vaccine, 30. Elsevier BV. https://doi.org/10.1016/j.vaccine.2012.05.090
12. Briganti, G., & Moine, O. L. (2020). Artificial Intelligence in Medicine: Today and Tomorrow. Frontiers in Medicine, 7. https://doi.org/10.3389/fmed.2020.00027
13. Burmeister, C. A., Khan, S. F., & Prince, S. (2024). Drugs and Drug Targets for the treatment of HPV-Positive Cervical Cancer [Review of Drugs and Drug Targets for the treatment of HPV-Positive Cervical Cancer]. Tumour Virus Research, 19, 200309. Elsevier BV. https://doi.org/10.1016/j.tvr.2024.200309
14. Castle, P. E. (2024). Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control [Review of Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control]. Viruses, 16(9), 1357. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/v16091357
15. Chang, A. (2019). The Role of Artificial Intelligence in Digital Health. In Computers in health care (p. 71). Springer International Publishing. https://doi.org/10.1007/978-3-030-12719-0_7

16. Chauhan, A. S., Prinja, S., Srinivasan, R., Rai, B., Malliga, J., Jyani, G., Gupta, N., & Ghoshal, S. (2020). Cost effectiveness of strategies for cervical cancer prevention in India. PLoS ONE, 15(9). https://doi.org/10.1371/journal.pone.0238291
17. Farina, E. M. J. de M., Nabhen, J. J., Dacoregio, M. I., Batalini, F., & Moraes, F. Y. de. (2022). An Overview of Artificial Intelligence in Oncology [Review of An Overview of Artificial Intelligence in Oncology]. Future Science OA, 8(4). Future Science Ltd. https://doi.org/10.2144/fsoa-2021-0074
18. Franco, E. L., Duarte-Franco, E., & Ferenczy, A. (2001). Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. PubMed, 164(7), 1017. https://pubmed.ncbi.nlm.nih.gov/11314432
19. Gaffney, D. K., Hashibe, M., Kepka, D., Maurer, K. A., & Werner, T. L. (2018). Too many women are dying from cervix cancer: Problems and solutions [Review of Too many women are dying from cervix cancer: Problems and solutions]. Gynecologic Oncology, 151(3), 547. Elsevier BV. https://doi.org/10.1016/j.ygyno.2018.10.004
20. Gakidou, E., Nordhagen, S., & Obermeyer, Z. (2008). Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities. PLoS Medicine, 5(6). https://doi.org/10.1371/journal.pmed.0050132
21. García-Saisó, S., Martí, M., Pesce, K., Luciani, S., Mújica, Ó. J., Hennis, A., & D'Agostino, M. (2024). Artificial Intelligence as a Potential Catalyst to a More Equitable Cancer Care. JMIR Cancer, 10. https://doi.org/10.2196/57276
22. Gentile, F., & Malara, N. (2024). Artificial intelligence for cancer screening and surveillance. ESMO Real World Data and Digital Oncology, 5, 100046. https://doi.org/10.1016/j.esmorw.2024.100046
23. Goel, I., Bhaskar, Y., Kumar, N., Singh, S. K., Amanullah, M., Dhar, R., & Karmakar, S. (2025). Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation [Review of Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation]. Frontiers in Digital Health, 7. Frontiers Media. https://doi.org/10.3389/fdgth.2025.1550407
24. Haghayegh, F., Norouziazad, A., Haghani, E., Feygin, A. A., Rahimi, R. H., Ghavamabadi, H. A., Sadighbayan, D., Madhoun, F., Papagelis, M., Felfeli, T., & Salahandish, R. (2024). Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies [Review of Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies]. Advanced Science. Wiley. https://doi.org/10.1002/advs.202400595
25. Harden, M. E., & Münger, K. (2016). Human papillomavirus molecular biology [Review of Human papillomavirus molecular biology]. Mutation Research/Reviews in Mutation Research, 772, 3. Elsevier BV. https://doi.org/10.1016/j.mrrev.2016.07.002
26. Hesse, B. W., Kwaśnicka, D., & Ahern, D. K. (2021). Emerging digital technologies in cancer treatment, prevention, and control [Review of Emerging digital technologies in cancer treatment, prevention, and control]. Translational Behavioral Medicine, 11(11), 2009. Oxford University Press. https://doi.org/10.1093/tbm/ibab033
27. Hou, X., Shen, G., Zhou, L., Li, Y., Wang, T., & Ma, X. (2022). Artificial Intelligence in Cervical Cancer Screening and Diagnosis [Review of Artificial Intelligence in Cervical Cancer Screening and Diagnosis]. Frontiers in Oncology, 12. Frontiers Media. https://doi.org/10.3389/fonc.2022.851367
28. Iqbal, M., Javed, Z., Sadia, H., Qureshi, I. A., Irshad, A., Ahmed, R., Malik, K., Raza, S., Abbas, A., Pezzani, R., & Sharifi-Rad, J. (2021). Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future [Review of Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future]. Cancer Cell International, 21(1). BioMed Central. https://doi.org/10.1186/s12935-021-01981-1
29. Jacobs, F., D'Amico, S., Zazzetti, E., Gaudio, M., Benvenuti, C., Saltalamacchia, G., Gerosa, R., Gentile, D., Lasagna, A., Pedrazzoli, P., Tinterri, C., Santoro, A., Sanctis, R. D., Porta, M. G. D.,

& Zambelli, A. (2024). Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems [Review of Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems]. Digital Health, 10. SAGE Publishing. https://doi.org/10.1177/20552076241288821

30. Li, Y.-H., Li, Y., Wei, M.-Y., & Li, G. (2024). Innovation and challenges of artificial intelligence technology in personalized healthcare [Review of Innovation and challenges of artificial intelligence technology in personalized healthcare]. Scientific Reports, 14(1). Nature Portfolio. https://doi.org/10.1038/s41598-024-70073-7
31. Lu, J., Song, E., Ghoneim, A., & Alrashoud, M. (2020). Machine learning for assisting cervical cancer diagnosis: An ensemble approach. Future Generation Computer Systems, 106, 199. https://doi.org/10.1016/j.future.2019.12.033
32. McCormack, M., Gaffney, D. K., Tan, D. S. P., Bennet, K., Chávez-Blanco, A., & Plante, M. (2021). The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries [Review of The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries]. International Journal of Gynecological Cancer, 31(5), 775. BMJ. https://doi.org/10.1136/ijgc-2021-002422
33. Mishra, G., Pimple, S., & Shastri, S. S. (2016). Prevention of Cervix Cancer in India [Review of Prevention of Cervix Cancer in India]. Oncology, 91, 1. Karger Publishers. https://doi.org/10.1159/000447575
34. Momenimovahed, Z., Mazidimoradi, A., Maroofi, P., Allahqoli, L., Salehiniya, H., & Alkatout, İ. (2022). Global, regional and national burden, incidence, and mortality of cervical cancer. Cancer Reports, 6(3). https://doi.org/10.1002/cnr2.1756
35. Murillo, R., Herrero, R., Sierra, M. S., & Forman, D. (2016). Cervical cancer in Central and South America: Burden of disease and status of disease control. Cancer Epidemiology, 44. https://doi.org/10.1016/j.canep.2016.07.015
36. Ngan, H., Garland, S. M., Bhatla, N., Pagliusi, S., Chan, K. K. L., Cheung, A., Chu, T., Domingo, E. J., Qiao, Y., Park, J. S., Tay, E. H., & Supakarapongkul, W. (2011). Asia Oceania Guidelines for the Implementation of Programs for Cervical Cancer Prevention and Control. Journal of Cancer Epidemiology, 2011, 1. https://doi.org/10.1155/2011/794861
37. Oualikene-Gonin, W., Jaulent, M., Thierry, J.-P., Oliveira-Martins, S. de, Belgodère, L., Maison, P., & Ankri, J. (2024). Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1437167
38. Papachristou, N., Kotronoulas, G., Δικαίος, N., Allison, S. J., Eleftherochorinou, H., Rai, T., Kunz, H. R., Barnaghi, P., Miaskowski, C., & Bamidis, P. D. (2023). Digital Transformation of Cancer Care in the Era of Big Data, Artificial Intelligence and Data-Driven Interventions: Navigating the Field. Seminars in Oncology Nursing, 39(3), 151433. https://doi.org/10.1016/j.soncn.2023.151433
39. Patel, S. K., George, B., & Rai, V. (2020). Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology [Review of Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology]. Frontiers in Pharmacology, 11. Frontiers Media. https://doi.org/10.3389/fphar.2020.01177
40. Rock, C. L., Michael, C. W., Reynolds, R. K., & Ruffin, M. T. (2000). Prevention of cervix cancer [Review of Prevention of cervix cancer]. Critical Reviews in Oncology/Hematology, 33(3), 169. Elsevier BV. https://doi.org/10.1016/s1040-8428(99)00073-6
41. Sanjosé, S. de, Brotons, M., LaMontagne, D. S., & Bruni, L. (2019). Human papillomavirus vaccine disease impact beyond expectations [Review of Human papillomavirus vaccine disease impact beyond expectations]. Current Opinion in Virology, 39, 16. Elsevier BV. https://doi.org/10.1016/j.coviro.2019.06.006

42. Sankaranarayanan, R., Bhatla, N., Gravitt, P. E., Basu, P., Esmy, P. O., Ashrafunnessa, K. S., Ariyaratne, Y., Shah, A., & Nene, B. M. (2008). Human Papillomavirus Infection and Cervical Cancer Prevention in India, Bangladesh, Sri Lanka and Nepal [Review of Human Papillomavirus Infection and Cervical Cancer Prevention in India, Bangladesh, Sri Lanka and Nepal]. Vaccine, 26. Elsevier BV. https://doi.org/10.1016/j.vaccine.2008.05.005
43. Shandilya, G., Gupta, S., Almogren, A., Bharany, S., Altameem, A., Rehman, A. U., & Hussen, S. (2024). Enhancing advanced cervical cell categorization with cluster-based intelligent systems by a novel integrated CNN approach with skip mechanisms and GAN-based augmentation. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-80260-1
44. Sharma, J., Madhavi, Y., & Priyanka, Y. (2023). Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review [Review of Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review]. Cureus. Cureus, Inc. https://doi.org/10.7759/cureus.41098
45. Sherris, J., Agurto, I., Arrossi, S., Dzuba, I. G., Gaffikin, L., Herdman, C., Limpaphayom, K., & Luciani, S. (2005). Advocating for cervical cancer prevention [Review of Advocating for cervical cancer prevention]. International Journal of Gynecology & Obstetrics, 89. Elsevier BV. https://doi.org/10.1016/j.ijgo.2005.01.010
46. Singh, D., Vignat, J., Lorenzoni, V., Eslahi, M., Ginsburg, O., Lauby-Secretan, B., Arbyn, M., Basu, P., Bray, F., & Vaccarella, S. (2022). Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health, 11(2). https://doi.org/10.1016/s2214-109x(22)00501-0
47. Thacharodi, A., Singh, P., Meenatchi, R., Ahmed, Z., Kumar, R. R. S., Neha, V., Kavish, S., Maqbool, M., & Hassan, S. (2024). Revolutionizing healthcare and medicine: The impact of modern technologies for a healthier future—A comprehensive review [Review of Revolutionizing healthcare and medicine: The impact of modern technologies for a healthier future—A comprehensive review]. Health Care Science, 3(5), 329. https://doi.org/10.1002/hcs2.115
48. Tiwari, A., Mishra, S. N., & Kuo, T. (2025). Current AI technologies in cancer diagnostics and treatment [Review of Current AI technologies in cancer diagnostics and treatment]. Molecular Cancer, 24(1). BioMed Central. https://doi.org/10.1186/s12943-025-02369-9
49. Torode, J., Kithaka, B., Chowdhury, R., Simelela, N., Cruz, J. L., & Tsu, V. (2021). National action towards a world free of cervical cancer for all women. Preventive Medicine, 144, 106313. https://doi.org/10.1016/j.ypmed.2020.106313
50. Vargas-Santiago, M., León-Velasco, D. A., Maldonado-Sifuentes, C. E., & Chanona-Hernández, L. (2025). A State-of-the-Art Review of Artificial Intelligence (AI) Applications in Healthcare: Advances in Diabetes, Cancer, Epidemiology, and Mortality Prediction [Review of A State-of-the-Art Review of Artificial Intelligence (AI) Applications in Healthcare: Advances in Diabetes, Cancer, Epidemiology, and Mortality Prediction]. Computers, 14(4), 143. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/computers14040143
51. Varnosfaderani, S. M., & Forouzanfar, M. (2024). The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century. Bioengineering, 11(4), 337. https://doi.org/10.3390/bioengineering11040337
52. Villa, L. L. (2012). Cervical Cancer in Latin America and the Caribbean: The Problem and the Way to Solutions. Cancer Epidemiology Biomarkers & Prevention, 21(9), 1409. https://doi.org/10.1158/1055-9965.epi-12-0147
53. Wu, E. S., Jerónimo, J., & Feldman, S. (2017). Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings [Review of Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings]. Journal of Global Oncology, 3(5), 572. American Society of Clinical Oncology. https://doi.org/10.1200/jgo.2016.007369

54. Wu, T., Lucas, É., Zhao, F., Basu, P., & Qiao, Y. (2024). Artificial intelligence strengthenes cervical cancer screening – present and future [Review of Artificial intelligence strengthenes cervical cancer screening – present and future]. Cancer Biology and Medicine, 1. Chinese Anti-Cancer Association. https://doi.org/10.20892/j.issn.2095-3941.2024.0198